Latest news

• Roche faces biosimilar blitz in 2018

  Novartis’unit Sandoz and Celltrion/Mundipharma’s Truxima have also claimed a European approval for its biosimilar versions of Roche’s immunotherapy drug MabThera (rituximab).

• Roche faces prospect of second Rituxan biosimilar in US

  It was the second biosimilar of Roche's drug to be approved in Europe after Celltrion/Mundipharma's Truxima, which also pipped Sandoz to the filing post in the US after

• Standing out in a crowd

  It followed that this year by gaining approval from the European Commission for the world’s first monoclonal antibody biosimilar of MabTera (rituximab), marketed as Truxima.

• Sandoz joins Europe's MabThera biosimilar push

  The approval - which comes four months after Celltrion/Mundipharma's Truxima biosimilar was cleared for marketing by the EMA - is for the entire range of indications awarded to MabThera, including ... Truxima claimed the distinction of being the first

• WHO pilots scheme to make biosimilars available to poorer countries

  Earlier this year the EMA approved Celltrion/Mundipharma's Truxima version of Rituxan, while other biosimilar copies of the drug have started to roll out in India, Latin America, and Russia,